In a randomized controlled trial, the GLP-1R agonist exenatide showed reduced alcohol intake in a subgroup of people with both obesity and alcohol use disorder
With GLP-1 medication, we aim to empower individuals to take control of their weight and overall health, ultimately improving their quality of life
When you combine appetite suppression from GLP-1 activation with the insulin-sensitizing effects of GIP stimulation and the thermogenic boost from glucagon receptor engagement, you get a compounding metabolic effect that no single-receptor or dual-receptor agonist can match
Always follow the exact compounded label and prescriber instructions
This trial tests retatrutide for obesity in adults without diabetes, using maintenance doses of 4mg, 9mg, and 12mg
took awhile to get going, but began losing weight Really easy to order and delivered on time